2021 annual meeting
The next 100 antibodies to be approved by FDA: emerging antibody modalities and beyond
Oct. 15, 2021, 7:30 p.m. US/Eastern
Zoom, Free for Everyone
Login to view recordings
Oct. 15, 2021, 7:30 p.m. US/Eastern
Zoom, Free for Everyone
Login to view recordings
In June 1986, FDA approved the first antibody drug in the US — muromonab-CD3 (Orthoclone OKT3). OKT3 comprises a murine monoclonal antibody against CD3 and it is used as an immunosuppressant for the treatment of acute transplant rejection. Since then, major technological advances have made the discovery and development of therapeutic antibodies much quicker and more efficient. In the next 35 years, more and more therapeutic antibodies were approved. In April 2021, FDA approved the 100th therapeutic antibody. The approval of the 100th therapeutic antibody marked a new journey for the global antibody drug industry.
Five years ago, also in April, more than 20 professionals in the field of therapeutic antibody gathered in Boston and established the Chinese Antibody Society, a nonprofit professional organization with the mission of building a platform that facilitates the communication and collaboration of the global community in the discovery, development, manufacturing, and commercialization of antibody-based products. From that day, the Chinese Antibody Society set off its own journey. In the past five years, the Chinese Antibody Society has grown exponentially. At the time when the Chinese Antibody Society turned to 5 years old, the Chinese Antibody Society has more than 2500 registered members, has its own peer-reviewed journal Antibody Therapeutics, has held more than 40 webinars and numerous on-site events. The annual conference of the Chinese Antibody Society has also become one of the most influential conference in the therapeutic antibody field.
Standing at the milestone of the approval of the 100th therapeutic antibody, the early approved antibody products are primarily in the form of traditional IgG antibodies. In recent years, more and more non-traditional antibody formats have emerged, including bispecific antibodies, trispecific antibodies, antibody-conjugated drugs (ADC), and some complex antibody drugs in various formats such as antibody + cell, antibody + nucleic acid, antibody + small molecule, antibody + protein/peptide, etc. It is expected to the therapeutic antibody field will soon enter the new era of AntibodyPlusTM integration. The AntibodyPlusTM integration is a brand-new concept recently proposed by the Chinese Antibody Society. We firmly believe that the integration of antibody with some other therapeutic modalities is the trend in next 5~10 years.
In view of the new trend in this field, Chinese Antibody Society is now pleased to hold the 2021 Annual Conference – “The next 100 antibodies to be approved by FDA: emerging antibody modalities and beyond” in October 2021. The annual conference will be held online via Zoom and free for registration to the public. In our two half-day events, speakers from both industry and academia will share their insights in diverse topics of antibody-based therapeutics and discuss the new trend AntibodyPlusTM integration. This event is a perfect opportunity for the attendees to stay up to date on the most recent progress and challenges in antibody-based drug development. We have invited distinguished guest speakers in biopharma industry and academia specializing in the field of therapeutic antibody. Online LIVE Q & A sessions will be included after every presentation. We sincerely invite you to join us online at
(1) Oct 15, 2021 evening starting at 7: 30 PM (US EDT)/Oct 16, 2021 morning starting at 7: 30 AM (Beijing Time); and
(2) Oct 16, 2021 evening starting at 7: 40 PM (US EDT)/Oct 17, 2021 morning starting at 7: 40 AM (Beijing Time).
Hover above speaker cards to read bio
Michael Yu, Ph.D.
CAS Board Director, CEO, Innovent Biologics
Mitchell Ho, Ph.D.
CAS Board Member, Senior Investigator, NIH
Fubao Wang, Ph.D.
CAS Board Member, SVP, AskLepios BioPharma
Zhaohui Zhou, Ph.D.
Professor, Northeastern University
Frederick W. Alt, Ph.D.
Professor, Harvard Medical School
Lianshan Zhang
President, Hengrui
Mark Chiu
President, Tavotek Bio Therapeutics
Shouye Wang, Ph.D.
CAS Founder, Board Member, CAS
Paul Carter, Ph.D.
President, The Antibody Society
Zhidan Tu, Ph.D.
President, CAS
Gary J. Nabel, Ph.D.
President, CEO, ModeX Therapeutics
Jinbo Xu, Ph.D.
Professor, Toyota Technological Institute
Pin Wang, Ph.D.
CSO, Simcere
Daotian Fu, Ph.D.
CAS Board Member, President, RemeGen
Hongtao Lu, Ph.D.
CSO, Elpiscience Biopharma
Aimin Hui
Executive President, Fosun Pharma
Jianmin Fang
CEO, RemeGen
Li Chen
Director, GenScript ProBio
Thomas Pillow
Principal Scientist, Genentech
Dehua Pei
Professor, OSU
Changshou Gao
CTO, Innovent Biologics
Kai Wucherpfennig, Ph.D.
Chair, Cancer Immunology and Virology, Dana-Farber Cancer Institute
Peter OCallaghan
Principle Scientist, Lonza
Chris Chen, Ph.D.
CEO, WuXi Biologics
Starts at 10/15/2021 7:30 p.m. US/Eastern
Hover to view abstract
10/15/2021 7:30 p.m. US/Eastern
Opening Remarks
Mitchell Ho, Ph.D., CAS Board Member, Senior Investigator, NIH
10/15/2021 7:45 p.m. US/Eastern
Review of CAS
Zhidan Tu, Ph.D., President, CAS
10/15/2021 8 p.m. US/Eastern
Partner Remarks
Paul Carter, Ph.D., President, The Antibody Society
10/15/2021 8:08 p.m. US/Eastern
Host of first day
Fubao Wang, Ph.D., CAS Board Member, SVP, AskLepios BioPharma
10/15/2021 8:10 p.m. US/Eastern
Session 1 Next Generation Antibodies for the Treatment of Cancer and Infections
Gary J. Nabel, Ph.D., President, CEO, ModeX Therapeutics
10/15/2021 8:40 p.m. US/Eastern
Session 1 Targeting the CD161 CLEC2D Pathway for Cancer Immunotherapy
Kai Wucherpfennig, Ph.D., Chair, Cancer Immunology and Virology, Dana-Farber Cancer Institute
10/15/2021 9:10 p.m. US/Eastern
Session 1 Improving Expression of Complex Proteins with a Toolbox Approach
Peter OCallaghan, Principle Scientist, Lonza
10/15/2021 10 p.m. US/Eastern
Session 2 Getting CAR T Cells to Work on Solid Tumors
Mitchell Ho, Ph.D., CAS Board Member, Senior Investigator, NIH
10/15/2021 10:30 p.m. US/Eastern
Session 2 Developing Covid19 Neutralizing Mabs at the Speed of Light
Chris Chen, Ph.D., CEO, WuXi Biologics
10/15/2021 11 p.m. US/Eastern
Panel Antibody Plus
Zhaohui Zhou, Ph.D., Professor, Northeastern University
10/16/2021 7:40 p.m. US/Eastern
Opening Remark
Michael Yu, Ph.D., CAS Board Director, CEO, Innovent Biologics
10/16/2021 7:55 p.m. US/Eastern
Opening Remark
Shouye Wang, Ph.D., CAS Founder, Board Member, CAS
10/16/2021 8:08 p.m. US/Eastern
Host of second day
Daotian Fu, Ph.D., CAS Board Member, President, RemeGen
10/16/2021 8:10 p.m. US/Eastern
Session 1 Chromatin Loop Extrusion Mediated Antibody Repertoire Diversification
Frederick W. Alt, Ph.D., Professor, Harvard Medical School
10/16/2021 8:40 p.m. US/Eastern
Session 1 Engineering T Cells for Cancer Immunotherapy
Pin Wang, Ph.D., CSO, Simcere
10/16/2021 9:10 p.m. US/Eastern
Session 1 Accelerated COVID19 Neutralizing Antibody Discovery by Integrated Multispecific Antibody Engineering Platform
Li Chen, Director, GenScript ProBio
10/16/2021 10 p.m. US/Eastern
Session 2 Creating an Immune Favorable Tumor Microenvironment for Tumor Immunotherapy
Hongtao Lu, Ph.D., CSO, Elpiscience Biopharma
10/16/2021 10:30 p.m. US/Eastern
Session 2 Protein Structure Prediction by Deep Learning
Jinbo Xu, Ph.D., Professor, Toyota Technological Institute
10/16/2021 11 p.m. US/Eastern
Panel Novel technologies in driving the development of next generation antibody and biologic therapeutics
Jingsong Wang, Ph.D., CEO, Harbour BioMed
10/17/2021 12:05 a.m. US/Eastern
Closing Remark
Daotian Fu, Ph.D., CAS Board Member, President, RemeGen
